|
|
Press Releases
Gamida Cell Reports StemEx® Phase II/III Study Safety and Efficacy Data
Apr. 11, 2013
Gamida Cell’s NiCord® Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study
Feb. 14, 2013
Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
Feb. 4, 2013
| Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma. |
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at Duke University
Nov. 12, 2012
Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product Nicord® For Hematological Malignancies
Sep. 19, 2012
Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s Lead Product StemEx® for Leukemia and Lymphoma
May. 15, 2012
The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Feb. 13, 2012
| The results of the StemEx study are expected during the second half of 2012 |
The Gamida Cell-Teva Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Jul. 12, 2011
The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx® for Leukemia and Lymphoma
Jun. 21, 2010
Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
Feb. 10, 2010
European Medicines Agency (EMA) Waives Requirement to Test StemEx® in Paediatric Patients 17 Years of Age and Under
Jan. 18, 2010
Gamida Cell Announces Feasibility Study with Weill Cornell Medical College
Dec. 2, 2009
| Study is testing a new method to deliver gene correction cells to treat congenital conditions such as Cooley's Anemia
|
StemEx® Noted as a Reliable Investigational Product of an Expanded Population of Stem Cells at Umbilical Cord Blood Symposium in Israel
Nov. 2, 2009
Article Published in Expert Opinion on Biological Therapy Evaluates StemEx® (carlecortemcel-l) for Leukemia and Lymphoma
Sep. 30, 2009
| The article, entitled Carlecortemcel-l, an ex vivo expanded umbilical cord
blood cell graft for allogeneic transplantation, is now available online. |
Children's Hospital in Colorado Enrolling for ExCell
Sep. 16, 2009
| Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemExֲ® for Leukemia and Lymphoma |
UPCI Joins ExCell Research Study
Jun. 15, 2009
| UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
|
Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
Jun. 3, 2009
| The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study. |
Cinco centros de trasplante de sangre de cordón umbilical se unen a un estudio
Jun. 3, 2009
| Cinco centros catalanes y valencianos de trasplante de sangre de cordón umbilical se unen a un estudio con una nueva técnica candidata a terapia contra la leucemia y el linfoma |
President of Israel Shimon Peres Tours Gamida Cell in Jerusalem
May. 20, 2009
| Gamida Cell is a world leader in adult stem cell technologies and products. |
The Western Pennsylvania Hospital Joins Prominent Group of Cancer Centers
Mar. 19, 2009
| The Western Pennsylvania Hospital Joins Prominent Group of Cancer Centers Exploring New Therapy for Leukemia and Lymphoma Patients.
ExCell study assessing the safety and efficacy of StemEx® as an alternative to bone marrow transplants
|
StemEx®, a Gamida Cell-TEVA Joint Venture Cell Therapy Product, Receives Orphan Medicinal Product Designation in the European Union
Mar. 11, 2009
| StemEx is now being researched in a Phase III study called ExCell assessing the safety and efficacy of StemEx as an alternative to bone marrow transplants for leukemia and lymphoma patients
|
Choc Children’s Joins Excell Pivotal Study For Leukemia And Lymphoma Patients As Only Pediatric Site On West Coast
Feb. 19, 2009
| Trial studying StemEx® as a bone marrow transplant alternative. |
Children’s Memorial Hospital Joins Excell Pivotal Study
Jan. 13, 2009
|
Press Releases Archive
•
•
•
•
•
•
•
|
